BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

394 related articles for article (PubMed ID: 22346751)

  • 1. The B-cell specific transcription factor, Oct-2, promotes Epstein-Barr virus latency by inhibiting the viral immediate-early protein, BZLF1.
    Robinson AR; Kwek SS; Kenney SC
    PLoS Pathog; 2012 Feb; 8(2):e1002516. PubMed ID: 22346751
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The B-cell-specific transcription factor and master regulator Pax5 promotes Epstein-Barr virus latency by negatively regulating the viral immediate early protein BZLF1.
    Raver RM; Panfil AR; Hagemeier SR; Kenney SC
    J Virol; 2013 Jul; 87(14):8053-63. PubMed ID: 23678172
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cellular transcription factor Oct-1 interacts with the Epstein-Barr virus BRLF1 protein to promote disruption of viral latency.
    Robinson AR; Kwek SS; Hagemeier SR; Wille CK; Kenney SC
    J Virol; 2011 Sep; 85(17):8940-53. PubMed ID: 21697476
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypoxia-inducible factor-1α plays roles in Epstein-Barr virus's natural life cycle and tumorigenesis by inducing lytic infection through direct binding to the immediate-early BZLF1 gene promoter.
    Kraus RJ; Yu X; Cordes BA; Sathiamoorthi S; Iempridee T; Nawandar DM; Ma S; Romero-Masters JC; McChesney KG; Lin Z; Makielski KR; Lee DL; Lambert PF; Johannsen EC; Kenney SC; Mertz JE
    PLoS Pathog; 2017 Jun; 13(6):e1006404. PubMed ID: 28617871
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cellular differentiation regulator BLIMP1 induces Epstein-Barr virus lytic reactivation in epithelial and B cells by activating transcription from both the R and Z promoters.
    Reusch JA; Nawandar DM; Wright KL; Kenney SC; Mertz JE
    J Virol; 2015 Feb; 89(3):1731-43. PubMed ID: 25410866
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BZLF1 governs CpG-methylated chromatin of Epstein-Barr Virus reversing epigenetic repression.
    Woellmer A; Arteaga-Salas JM; Hammerschmidt W
    PLoS Pathog; 2012 Sep; 8(9):e1002902. PubMed ID: 22969425
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Viral genome methylation differentially affects the ability of BZLF1 versus BRLF1 to activate Epstein-Barr virus lytic gene expression and viral replication.
    Wille CK; Nawandar DM; Panfil AR; Ko MM; Hagemeier SR; Kenney SC
    J Virol; 2013 Jan; 87(2):935-50. PubMed ID: 23135711
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PARP1 restricts Epstein Barr Virus lytic reactivation by binding the BZLF1 promoter.
    Lupey-Green LN; Moquin SA; Martin KA; McDevitt SM; Hulse M; Caruso LB; Pomerantz RT; Miranda JL; Tempera I
    Virology; 2017 Jul; 507():220-230. PubMed ID: 28456021
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of ARKL1 as a Negative Regulator of Epstein-Barr Virus Reactivation.
    Siddiqi UZ; Vaidya AS; Li X; Marcon E; Tsao SW; Greenblatt J; Frappier L
    J Virol; 2019 Oct; 93(20):. PubMed ID: 31341047
    [TBL] [Abstract][Full Text] [Related]  

  • 10. B cells infected with Type 2 Epstein-Barr virus (EBV) have increased NFATc1/NFATc2 activity and enhanced lytic gene expression in comparison to Type 1 EBV infection.
    Romero-Masters JC; Huebner SM; Ohashi M; Bristol JA; Benner BE; Barlow EA; Turk GL; Nelson SE; Baiu DC; Van Sciver N; Ranheim EA; Gumperz J; Sherer NM; Farrell PJ; Johannsen EC; Kenney SC
    PLoS Pathog; 2020 Feb; 16(2):e1008365. PubMed ID: 32059024
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reactivation of Epstein-Barr Virus by HIF-1α Requires p53.
    Kraus RJ; Cordes BA; Sathiamoorthi S; Patel P; Yuan X; Iempridee T; Yu X; Lee DL; Lambert PF; Mertz JE
    J Virol; 2020 Aug; 94(18):. PubMed ID: 32641480
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IRF4 promotes Epstein-Barr virus activation in Burkitt's lymphoma cells.
    Gao Y; Wang L; Lei Z; Li J; Forrest JC; Liang X
    J Gen Virol; 2019 May; 100(5):851-862. PubMed ID: 30907723
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The lytic phase of epstein-barr virus requires a viral genome with 5-methylcytosine residues in CpG sites.
    Kalla M; Göbel C; Hammerschmidt W
    J Virol; 2012 Jan; 86(1):447-58. PubMed ID: 22031942
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Shutoff of BZLF1 gene expression is necessary for immortalization of primary B cells by Epstein-Barr virus.
    Yu X; McCarthy PJ; Wang Z; Gorlen DA; Mertz JE
    J Virol; 2012 Aug; 86(15):8086-96. PubMed ID: 22623769
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epstein-Barr virus BZLF1 gene, a switch from latency to lytic infection, is expressed as an immediate-early gene after primary infection of B lymphocytes.
    Wen W; Iwakiri D; Yamamoto K; Maruo S; Kanda T; Takada K
    J Virol; 2007 Jan; 81(2):1037-42. PubMed ID: 17079287
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reactivation of Epstein-Barr Virus from Latency Involves Increased RNA Polymerase Activity at CTCF Binding Sites on the Viral Genome.
    Dunn LEM; Lu F; Su C; Lieberman PM; Baines JD
    J Virol; 2023 Feb; 97(2):e0189422. PubMed ID: 36744959
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BZLF1 interacts with chromatin remodelers promoting escape from latent infections with EBV.
    Schaeffner M; Mrozek-Gorska P; Buschle A; Woellmer A; Tagawa T; Cernilogar FM; Schotta G; Krietenstein N; Lieleg C; Korber P; Hammerschmidt W
    Life Sci Alliance; 2019 Apr; 2(2):. PubMed ID: 30926617
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ceramide promotes lytic reactivation of Epstein-Barr virus in gastric carcinoma.
    Kim JY; Min YJ; Lee M-H; An YR; Ashktorab H; Smoot DT; Kwon SW; Lee SK
    J Virol; 2024 Feb; 98(2):e0177623. PubMed ID: 38197630
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hippo signaling effectors YAP and TAZ induce Epstein-Barr Virus (EBV) lytic reactivation through TEADs in epithelial cells.
    Van Sciver N; Ohashi M; Pauly NP; Bristol JA; Nelson SE; Johannsen EC; Kenney SC
    PLoS Pathog; 2021 Aug; 17(8):e1009783. PubMed ID: 34339458
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MicroRNA miR-BART20-5p stabilizes Epstein-Barr virus latency by directly targeting BZLF1 and BRLF1.
    Jung YJ; Choi H; Kim H; Lee SK
    J Virol; 2014 Aug; 88(16):9027-37. PubMed ID: 24899173
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.